Trials / Completed
CompletedNCT04130828
Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Prince of Songkla University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Iron deficiency anemia is a global health problem and the most common cause of anemia worldwide. Patients with iron deficiency and Iron deficiency anemia can present with a multitude of symptoms including fatigue, dyspnea on exertion, dysphagia, pallor, palpitations, headaches, tinnitus, taste disturbance and pica. Oral iron supplementation is associated with increasing hemoglobin in multiple studies in women, pregnant women and elderly patients. However, the optimal dose and frequency of oral iron supplementation for treatment remains unclear. The current proposed study attempts to address this gap in the literature.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ferrous Fumarate | Ferrous fumarate 200 mg PO PC |
Timeline
- Start date
- 2020-01-21
- Primary completion
- 2022-01-18
- Completion
- 2022-01-18
- First posted
- 2019-10-17
- Last updated
- 2022-02-15
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT04130828. Inclusion in this directory is not an endorsement.